Beyond GLP-1s | Sloan Saunders’ Holistic Vision for Sustainable Obesity Treatment

The obesity epidemic demands solutions that go beyond temporary fixes or single-medication approaches. While drugs like GLP-1 agonists dominate headlines, lasting change requires reimagining care delivery, addressing systemic inefficiencies, and tackling root causes. Enter Sloan Saunders, a former investment banker turned healthcare innovator, whose company FlyteHealth is pioneering a holistic model for obesity treatment—one that merges financial strategy, advanced technology, and patient-centered care.

After a 15-year career in banking and private equity, Sloan co-founded FlyteHealth to confront the gaps he saw in obesity care: outdated clinical practices, fragmented insurance coverage, and an over-reliance on short-term interventions. Selected for the UCSF Rosenman Innovators Program in 2022, FlyteHealth now partners with employers, payers, and health systems—including a groundbreaking initiative with the state of Connecticut—to deliver scalable, cost-effective care that prioritizes long-term health over quick fixes.

In this episode, Sloan shares his unconventional leap from finance to healthcare entrepreneurship, the lessons that shaped FlyteHealth’s mission, and how technology tackles clinical inefficiencies to personalize care and address root causes. He also offers insights into the future of obesity treatment, from employer partnerships to redefining health investments. Tune in for a candid conversation about disrupting norms, overcoming founder challenges, and building solutions that prove sustainable obesity care is possible—when we look beyond the prescription pad.

Do you have thoughts on this episode or suggestions for future guests? We’d love to hear from you. Email us at hello@rosenmaninstitute.org.